$5.60
0.00 (0%)
Indevus Pharmaceuticals (IDEV.DL)
CAPS Rating:
A biopharmaceutical company engaged in the acquisition, development and commercialization of products to treat urological, gynecological and men's health conditions.

RSS Headlines
Fool UK
Recs
Indevus was bid down as a result of FDA conditions for new drug nebido.Traders have ignored the fact that the company has other products on the market.Sanctura &sanctura xr,Vantas,supprelin, and delastestryl. Earned 60mi in revenue & royaltys this yr. Alergon, maker of Botex is Indevus partner for marketing sanctura, cant get much better.Seven more drugs in development.Valstar,a bladder cancer drug is most advanced. No huge sellers, but combined it makes a pretty good revenue stream.